Introduction
============

There are increasing applications of Chinese herbal medicines (CHMs) for the prevention and treatment of various illnesses, and in parallel, the increased use has been accompanied by an emerging concern regarding the safety of CHMs ([@B52]; [@B45]; [@B40]). Cases of severe adverse effects caused by CHMs, particularly hepatotoxicity, have been frequently reported over the past few decades ([@B39]; [@B5]; [@B9]). Several CHMs have been identified as a major cause of drug-induced liver injury, namely herb-induced liver injury (HILI), for example, Polygoni Multiflori Radix (He-Shou-Wu in Chinese) was pointed out to use with caution for the severe hepatotoxicity ([@B27]; [@B24]). Undoubtedly, it is important to pay attention to the health risk of CHMs.

Dictamni Cortex (DC, Bai-Xian-Pi in Chinese) (**Figure [1A](#F1){ref-type="fig"}**) is the root bark of *Dictamnus dasycarpus* Turcz. (Family Rutaceae), which is extensively spread throughout China and has been used as a CHM for the treatment of rheumatism, jaundice, skin diseases and chronic hepatitis with a long history ([@B11]; [@B28]; [@B6]). However, the safety of DC has been questioned as exposure to DC might be associated with the risk of hepatitis in clinic ([@B3]; [@B12]). A systematic review in Korea reported that 37.1% of identified HILI cases were attributed to DC ([@B23]). Additionally, an investigation in mice and rats showed that oral administration of DC aqueous extract led to sub-chronic toxicity with alterations of hematological and liver function parameters ([@B41]). Although chemical studies had been extensively conducted and a large number of compounds, including quinolone alkaloids ([@B11]; [@B36]), furoquinoline alkaloids ([@B1]; [@B28]) and limonoides ([@B35]), were isolated in DC, the hepatotoxicity-related causal ingredients remain unidentified so far.

![Dictamni Cortex **(A)** and chemical structure of dictamnin (DTN) **(B)**.](fphar-09-01033-g001){#F1}

It is widely accepted that cytochrome P450 (CYPs)-mediated metabolic activation is responsible for the hepatotoxicity of some natural products ([@B29]; [@B32]; [@B26]) via the formation of reactive electrophilic intermediates that react with nucleophilic sites of macromolecules, such as protein ([@B46]), glutathione ([@B18]), and nucleic acid ([@B49]). Among those potential toxic natural products, furan-containing compounds are representatives that are prone to be bioactivated into an epoxide or a *cis*-enedione intermediate, which could bind with cellular proteins and thereby trigger toxicity ([@B30]). In this aspect, a striking example was disobulbin B, a furanoid diterpenoid lactone isolated from *Dioscorea bulbifera* L., which was proven to be hepatotoxic through metabolic activation of the furan moiety in the presence of CYP 3A ([@B25]). Consequently, the furan ring moiety is considered to be an alert structure for medicinal chemists and risk assessors ([@B19]).

Given that dictamnine (DTN, **Figure [1B](#F1){ref-type="fig"}**), a major furoquinoline alkaloid component in DC, possesses a furan ring in its molecular structure, we hypothesized that DTN might be potentially responsible for DC-induced hepatotoxicity. Actually, [@B15] found that DTN damaged the mitochondrial membrane and exerted cytotoxicity. More importantly, it was confirmed that DTN was predominantly metabolized into an epoxide intermediate (2,3-epoxide) *in vitro*, which was primarily in the participation of CYP3A4 ([@B43]). Furthermore, the epoxide intermediate could subsequently conjugated with *N*-acetylcysteine to form conjugate with CYP3A4 was primarily responsible for the metabolic activation process ([@B13]). Thus, evidences have shown the link between the metabolic activation of DTN and CYP3A4, namely CYP3A4 was the predominant enzyme involved in the metabolism of DTN. However, the correlation between CYP3A4-mediated metabolism and DTN-induced hepatotoxicity was not clear.

Therefore, in an attempt to define the correlation, we evaluated the toxicological and histopathological responses with CYP3A4 inducer and inhibitor. The correlation was unveiled by comparison studies at three levels: (1) cytotoxicity of DTN in different CYP3A4 expression cells, including primary human hepatocytes (PHH) with CYP3A4 inducer or inhibitor, NIH3T3 cells, wild type (WT) HepG2 and L02 cells, and stable CYP3A4 over-expressed (OE) HepG2 and L02 cells with CYP3A4 inducer or inhibitor; (2) biochemical and histopathological differences in DTN-induced hepatotoxicity with or without CYP3A4 induction/inhibition in mice; (3) differences of pharmacokinetic parameters between CYP3A4 inhibition groups and non-pretreatment groups in mice. Based on the obtained results of this study, we confirmed the vital modulatory role of CYP3A4 in DTN-associated hepatotoxicity. **Figure [2](#F2){ref-type="fig"}** displayed the overall research strategy for this study.

![Scheme for the study. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group.](fphar-09-01033-g002){#F2}

Materials and Methods {#s1}
=====================

Reagents and Materials
----------------------

Dictamnine and γ-fagarine (\>98% purity) were purchased from Chengdu Must Biotechnology Co., Ltd. (Chengdu, China). Dexamethasone (DEX), rifampicin (RIF), ketoconazole (KTZ), diclofenac sodium (DCF), corn oil, CMC-Na and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) were products of Aladdin Chemical Co., Ltd. (Shanghai, China). A neutral red kit was procured from Beyotime Biotechnology Co., Ltd. (Shanghai, China). Gibco^®^ high glucose Dulbecco's modified Eagle's medium (DMEM) and lipo2000 were obtained from Thermo Fisher Scientific Technology Co., Ltd. (Shanghai, China). Medium for PHH was purchased from Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China). A PCR kit was purchased from Vazyme Biotech Co. Ltd. (Nanjing, China). All other chemical reagents were from Merck Life Science Co., Ltd. (Shanghai, China).

Animals and Treatment
---------------------

Male adult ICR mice (20 ± 2 g) were supplied by the Model Animal Research Center of Nanjing University (Nanjing, China). All experiments and animal care were conducted in accordance with the Provision and General Recommendation of Chinese Experimental Animals Administration Legislation and were approved by the Science and Technology Department of Jiangsu Province \[license number: SYXK (SU) 2016-0011\]. The mice were housed in a controlled temperature and humidity of 22 ± 2°C and 55 ± 5%, respectively, and maintained on a 12 h light/dark cycle with free access to food and water. Mice were fastened for 12 h and free to water before treatment.

Mice were randomly assigned into two groups for different treatment. The protocol was conducted as previously described with minor modification ([@B16]; [@B25]). The mice in group A (*n* = 4) were pretreated with DEX (70 mg/kg, dissolved in corn oil) or vehicle by intraperitoneal (*i.p.*) injection for 3 consecutive days, and 1 h after the last injection, a single dose of DTN (640 mg/kg, suspended in 0.5% CMC-Na) or vehicle was orally administrated to the mice. Mice in group B (*n* = 4) were treated with DTN (320 mg/kg) for 4 consecutive days, and 1.5 h before the last administration of DTN (640 mg/kg) on the 5th day, mice were treated with KTZ (75 mg/kg, dissolved in corn oil) or vehicle by *i.p.* injection. Blood and liver tissues were collected in 24 h following treatment. All the livers were quickly removed and the left lateral liver lobes were used for histopathological examinations.

Cell Culture
------------

Cryo-preserved PHH were supplied by the Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China; Lot No. 24595), and cultured in the supporting complete medium. HepG2, L02, and NIH3T3 cells were preserved in the State Key Laboratory of Natural Medicines (Nanjing, China). HepG2 and L02 cells, including CYP3A4 OE cells, were maintained in DMEM medium containing 10% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin, while NIH3T3 cells were cultured in DMEM with 10% calf serum instead of fetal bovine serum. Prior to any treatment, cells were trypsinized and plated in a decent destiny with the corresponding media at 37°C in an incubator with a humidified atmosphere of 5% CO~2~/95% air.

Construction of Stable CYP3A4 OE HepG2 and L02 Cell Lines
---------------------------------------------------------

The 1512-bp fragment containing the human CYP3A4 coding sequence plasmid (pCMV3-CYP3A4-GFPspark) was obtained from Sino Biological Inc. (Beijing, China). Cells were seeded into 100-mm culture dishes at a density of 1 × 10^6^ cells, and 24 h later cells were transfected with the above plasmid (1000 ng of DNA per dish) and lipo2000 according to the manufacturer's instruction. The successful transfected cells expressed green fluorescent protein (GFP) and showed green fluorescence under fluorescence microscope (Nikon Corp., Tokyo, Japan). 24 h later, the medium was changed with hygromycin B (50 mg/mL) every 3rd day to a final concentration of 400 and 500 μg/mL for HepG2 and L02, respectively. Cells were allowed to grow in the selection medium for 4 weeks, at which time individual clonal expansions (clones) were visible. Each clone was transferred and tested for enzymatic activity by a quantitative polymerase chain reaction (Q-PCR), western blot analysis and determining hydroxylation of testosterone. DCF, a known hepatotoxic drug through metabolic activation by CYP3A4 ([@B34]; [@B4]) was chosen as the positive control to verify the effect of CYP3A4 in the WT and OE cells.

Characterization of CYP3A4 Enzyme Activity in HepG2 and L02 Cells
-----------------------------------------------------------------

The experiment was conducted referring to [@B17] with modification. Briefly, the CYP3A4 over-expressed (OE) and WT HepG2 and L02 cells were seeded into a six-well plate with a density of 8 × 10^4^ to 1 × 10^5^ cells/per well. Cells were incubated with the substrate testosterone (30 μM), which was from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China). The reaction was terminated by 2.4 mL of ice-cold acetonitrile containing an internal standard (9-aminoacridine, IS1) after 48 h exposure. The supernatant was collected, centrifuged at 12,000 × *g* for 10 min. 3.5 mL of supernatant was collected and dried (GeneVac EZ-2, England). The residue was reconstituted with 10% methanol (100 μL), centrifuged at 12,000 × *g* for 10 min. The supernatant was collected and 2 μL was to be analyzed with method A by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Cytotoxicity Evaluation of PHH, HepG2, L02, and NIH3T3 Cells
------------------------------------------------------------

The experiment in PHH was divided into two groups: cells were seeded at respective cell densities of 5 × 10^3^ and 2 × 10^3^, and then incubated for 24 h. The first group was incubated with KTZ (10 μM) for 2 h before DTN exposure ([@B20]), and another group was pre-incubated with RIF (20 μM) for 72 h ([@B51]). After that, cells were treated with gradient concentrations of DTN, DCF, and DMSO (solvent control) for 24 h. All of the compounds were dissolved in DMSO with the final concentration of DMSO was less than 0.2% in the incubation system. The MTT assay was employed and the optical density (OD) value was measured at 490 nm with a microplate reader (BioTek Instruments, Winooski, VT, United States).

The neutral red assay was performed to assess cell viability of NIH3T3 cells. Briefly, cells were seeded into a 96-well plate at a density of 8 × 10^3^ cells per well, incubated for 12 h, and then exposed to DTN and DMSO. After incubation, the neutral red reagent was added following the manufacturer's instruction. The OD value was detected at 570 nm. The WT and CYP3A4 OE HepG2 and L02 were treated in the same manner as NIH3T3 cells, and cell viability was measured by MTT assay. Cell viability was calculated with the following equation (Eq. 1). OD value is presented as the mean ± SD from three independent replicate experiments.
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Q-PCR of WT, CYP3A4 OE HepG2 and L02 Cells, and Mice Liver Tissues
------------------------------------------------------------------

HepG2 and L02 cells (5 × 10^4^) were seeded and cultured in six-well plates. The success of transduction was assessed by fluorescence microscope. Thereafter, mRNA expressions of human CYP3A4 in the CYP3A4 OE HepG2 and L02 cells were determined by Q-PCR. Total RNA was extracted with TRIzol reagent (Vazyme Biotech Co., Ltd., Nanjing, China). The RNA quality was assessed with a Thermo Nanodrop Analyzer and only RNAs with OD~260~/OD~280~ ranging from 1.8 to 2.0 were used for further experiments. The primers (**Table [1](#T1){ref-type="table"}**) were from Genscript Biotech Co., Ltd. (Nanjing, China), and reserve transcription was performed with a kit (Vazyme Biotech Co., Ltd., Nanjing, China) according to the manufacture's instruction. The reverse reactions with a system containing 1000 ng of RNA were performed at 25°C for 10 min, 50°C for 30 min and 85°C for 5 min. PCR was performed on a Light Cycle 96 Real-time PCR system (Roche, Basel, Switzerland). In addition, 20 mg of each mouse liver sample was weighed, and homogenized with 1 mL TRIzol at 60 Hz for 30 s in 4°C. The supernatant was separated to extract the RNA. Other procedures were the same as described except that mouse primers were used (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). Human and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as control.

###### 

Sequences of primer pair used for PCR amplification.

  Target genes   5′ → 3′ primer sequence (Forward)   5′ → 3′ primer sequence (Reverse)
  -------------- ----------------------------------- -----------------------------------
  hGAPDH         CCATGTTCGTCA TGGGTGTGAAC            GCCAGTAGAGGC AGGGATGATGTTC
  hCYP3A4        CCTCCCTGAAAG ATTCAGCA               ATGAGAGCAAAC CTCATGCC
                                                     

Western Blot Analysis
---------------------

Cells were lysed with lysis buffer, and then heated at 99°C in a metal bath for 30 min to denature proteins. After separation of protein (equal loading for each sample) by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 100 μg of protein samples were electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane at 250 mA for 60 min. After blocking with phosphate buffered saline containing 0.1% Tween--20 (PBST) and 5% fat-free milk for 1 h, PVDF membranes were immunoblotted overnight at 4°C with rabbit anti-GFP tag (1:1000 dilution) (ABclonal Biotech Co., Ltd., Boston, MA, United States) and anti-actin (1:1000 dilution), followed by incubation with rabbit secondary horseradish peroxidase conjugated antibody (1: 2000 dilution) for 1 h at room temperature. After washing the membranes three times with PBST, immunoreactive bands were visualized via a Tanon Western blot detection system (Tanon Science and Technology Co., Ltd., Shanghai, China). Human β-actin was used as a loading control.

Biochemical Assay and Histopathological Examinations
----------------------------------------------------

The collected blood samples were allowed to clot at room temperature, followed by centrifugation at 4°C, 1,000 × *g* for 10 min. The resulting sera were immediately sent for alanine transaminase (ALT) and aspartate aminotransferase (AST) assays to the laboratory in Jiangsu Province Hospital of Traditional Chinese and Western Medicine (Nanjing, China) on ice. The testing laboratory was authenticated with ISO15189 and the assay was performed in a Roche Cobas 8000 (ISE/701/701/502) automatic biochemical analyzer. Liver tissues were immediately fixed in 4% paraformaldehyde for at least 24 h, then paraffin-processed, and sectioned into 3-μm thick slices. The sections were stained with hematoxylin and eosin (H&E), and finally evaluated by a pathologist using an optical microscope.

Pharmacokinetic Study
---------------------

Mice (*n* = 4 for each time point) were orally treated with DTN (320 mg/kg, suspended in 0.5% CMC-Na) for 4 consecutive days, and 1.5 h before the last administration of DTN (640 mg/kg) on the 5th day, mice were treated with KTZ (75 mg/kg, dissolved in corn oil) or vehicle by *i.p.* injection. Blood samples were collected by cardiac puncture at time intervals of 0.16, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after DTN administration. Aliquots (50 μL) of sera were mixed with 400 μL methanol containing γ-fagarine (final concentration was 20 ng/mL) as the IS2. The resulting mixture was vortex-mixed and centrifuged at 16,000 × *g* for 10 min to remove precipitated protein. The resulting supernatants were analyzed in method B by LC-MS/MS. A non-compartmental model was utilized to describe the serum concentration-time profiles of DTN. Pharmacokinetic parameters, including maximum serum concentration (*C*~max~), time to reach maximum serum concentration (*T*~max~), area under the serum concentration-time curve (AUC) and *t*~1/2~ were determined with DAS software (Version 2.0, Mathematical Pharmacology Professional Committee of China, Shanghai, China).

LC-MS/MS Analysis
-----------------

Analyses were conducted on an Agilent series 1260 LC system and an Agilent 6420 QqQ mass spectrometer (Agilent Technologies, Santa Clara, CA, United States). Method A was as follows: The separation was carried out on a Waters Cortecs column (2.1 mm × 150 mm, 1.6 μm) at 35°C. Acetonitrile and water containing 0.1% (*v/v*) formic acid was adopted as the mobile phase, the flow rate was 0.3 mL/mi. The gradient was as follows: 0--3 min, 8--25% B; 3--5 min, 25--70% B; 5--7 min, 70--8% B. Method B was as follows: The separation was carried out on an Agilent Poroshell 120 SB-C~18~ column (4.6 mm × 75 mm, 2.7 μm) at 30°C. Methanol/water (75/25, *v/v*) containing 0.1% (*v/v*) formic acid was adopted as the mobile phase, the flow rate was 0.3 mL/min, and the injection volume was set at 2 μL.

The mass spectrometer was operated in positive ion mode with electrospray ionization source. Quantitation was performed by multiple reaction monitoring mode. The characteristics of ion pairs, corresponding fragmentor and collision energy in method A for 6β-hydroxyl testosterone (6β-OHTST) were *m/z* 305 → 269 (130 V, 12 V), and those for corresponding IS1 were *m/z* 195 → 151 (120 V, 50 V); while the parameters in method B for DTN were *m/z* 200 → 185 (135 V, 35 V), and those for corresponding IS2 were *m/z* 230 → 200 (135 V, 30 V). Data collection and processing were conducted with MassHunter Workstation 07.00 (Agilent Technologies, Santa Clara, CA, United States).

Statistical Analysis
--------------------

All data are expressed as the mean ± SD. Figures were obtained by the GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, United States). Statistical analyses were performed using SPSS 19 (IBM Corp., Albany, NY, United States). Differences between many groups at one level were tested by one-way ANOVA with Bonferroni's *post hoc* test if the data were normally distributed. In the case of non-normally distributed data, Tamhane's T2 statistics was performed. Differences between two groups were carried out using a two-tailed Student's *t*-test. In all cases, a *p*-value less than 0.05 was considered to be significant.

Results
=======

Cytotoxicity of DTN in PHH, HepG2, L02, and NIH3T3 Cells
--------------------------------------------------------

The EC~50~ values of DTN between hepatocytes and non-hepatocytes NIH3T3 cells were compared. As shown in **Figures [3A,B](#F3){ref-type="fig"}**, the EC~50~ value in PHH was 0.32 mM, which was minimal, and the values in L02 cells (0.56 mM) and HepG2 cells (0.77 mM) were approximative. Nevertheless, the EC~50~ value in NIH3T3 cells (incubation for up to 72 h) was 2.6 mM, which was 8.3, 3.4, and 4.7 times higher than that in PHH, HepG2, and L02 cells, respectively. Meanwhile, the cell inhibition ratio was marginal in NIH3T3 cells after DTN treatment (100--1200 μM) with cell viabilities ranging from 77.9 to 94.7%. Hence, DTN was unable to induce cytotoxicity in NIH3T3 cells with free CYP3A4 expression. The above results indicated that DTN exhibited varied cytotoxicity in diverse cells with different CYP3A4 expression levels.

![Cytotoxicity of DTN in primary human hepatocytes (PHH), L02, HepG2 for 24 h and NIH3T3 cells for 72 h **(A)**. EC~50~ values in different cells **(B)**. Data are represented as mean ± SD (*n* = 3).](fphar-09-01033-g003){#F3}

The Effect of Inhibition and Induction of CYP3A4 on Cytotoxicity of DTN in PHH
------------------------------------------------------------------------------

As shown in **Figure [4A](#F4){ref-type="fig"}**, in the presence of KTZ, the cell viability of PHH was remarkably increased when treated with 1 mM DCF (positive control) for 24 h. Within the DTN concentration of 100--800 μM, the cytotoxicity was exacerbated and appeared to be dose-dependent. When treated with DTN+KTZ (10 μM), the cell viabilities at all tested concentrations showed significant decreases compared to the solvent group. The cytotoxicity of DTN (100--800 μM) co-treated with KTZ was statistically significant decreased by 2.63--8.65% in comparison with the DTN sole group. Moreover, the EC~50~ value was significantly increased in the KTZ pretreated group (**Figure [4C](#F4){ref-type="fig"}**).

![The effect of inhibition and induction of CYP3A4 on the cytotoxicity of DTN in PHH pretreated with KTZ **(A,C)** and RIF **(B,D)**, respectively. Data are represented as mean ± SD (*n* = 3). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01 vs. DTN group.](fphar-09-01033-g004){#F4}

The cell viability of PHH pre-incubated with RIF was significantly decreased when treated with 1 mM DCF (**Figure [4B](#F4){ref-type="fig"}**). Cytotoxicity of both DTN and DTN+RIF groups were significantly decreased compared with solvent control. At 100--800 μM of DTN, co-treatment with RIF resulted in a statistically significant decrease in cell viability (by 3.91--6.23%) and EC~50~ value compared to the DTN group (**Figure [4D](#F4){ref-type="fig"}**). In brief, when the activity of CYP3A4 was inhibited by KTZ *in vitro*, the cytotoxicity of DTN was alleviated, and once induced by RIF, the cytotoxicity was exacerbated.

The Effect of Over-Expression of CYP3A4 on the Cytotoxicity of DTN in HepG2 and L02 Cells
-----------------------------------------------------------------------------------------

The stable CYP3A4 OE HepG2 and L02 cells were successfully built and verified. Both the OE cells showed green fluorescence under a fluorescence microscope (**Figures [5A,B](#F5){ref-type="fig"}**). The relative mRNA expression level of CYP3A4 in OE HepG2 and L02 cells was 2,700 and 13, 000 times higher than corresponding WT cells, respectively (**Figure [5C](#F5){ref-type="fig"}**). Both OE cells showed a GFP-CYP3A4 protein band simultaneously (**Figure [5D](#F5){ref-type="fig"}**). Furthermore, the enzyme activity of CYP3A4 was characterized through detecting the amount of 6β-hydroxyl testosterone in the respective cells incubating with testosterone (the classic substrate of CYP3A4) (**Figure [6](#F6){ref-type="fig"}**), which demonstrated that stable CYP3A4 OE cells were successfully constructed. The cytotoxicity comparison of DTN between CYP3A4 OE HepG2, L02 cells and the corresponding WT cells was performed. In addition, inhibition effect of KTZ on the OE cells was also explored. According to the cell viability and time curves, incubation for 48 and 24 h in OE HepG2 and L02 cells was, respectively, selected (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**).

![Characterization of wild type (WT) and stable CYP3A4 over-expressed (OE) HepG2 and L02 cells through **(A)** monitoring under white light, **(B)** monitoring under fluorescent light, **(C)** PCR and **(D)** Western blot. β-actin served as loading control (Original magnification 100×; the scale bar is 100 μm). ^∗∗^*p* \< 0.01 vs. WT cells.](fphar-09-01033-g005){#F5}

![Oxidation of testosterone to 6β-hydroxyl-testosterone in WT and CYP3A4 OE HepG2 cells **(A)** and L02 cells **(B)**. Values are represented as mean ± SD (*n* = 3). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. WT groups.](fphar-09-01033-g006){#F6}

Compared with WT cells, the cell viabilities in CYP3A4 OE HepG2 and L02 cells were greatly decreased when treated with DCF (400--2000 μM), and the decreased cell viability in both OE cells could be reversed by KTZ, which demonstrated that the model was suitable to validate the impact of CYP3A4 on the cytotoxicity (**Figures [7A,C](#F7){ref-type="fig"}**). When treated with DTN, the cell viability in OE HepG2 cells was significantly lower compared with WT HepG2 cells with the decrease ranging from 6.7 to 13.7% (**Figure [7B](#F7){ref-type="fig"}**). Furthermore, the cytotoxicity in OE HepG2 cells pretreated with KTZ was significantly decreased with the increase of cell viability from 5.9 to 36.8% compared with the OE cells. Meanwhile, the MTT assay showed that the cell viability in OE L02 cells was indeed decreased compared with WT cells after 24 h of DTN exposure, with decrease of cell viabilities ranging from 7.1 to 68.8% (**Figure [7D](#F7){ref-type="fig"}**). Similarly, co-incubation with KTZ could mitigate the cytotoxicity in OE L02 cells caused by CYP3A4 over-expression with cell viability increasing from 17.1 to 56.5%. Therefore, DTN elicited significantly higher cytotoxic effects in the CYP3A4 over-expressed HepG2 and L02 cells, and inhibition of CYP3A4 alleviated the cytotoxicity, which further revealed that CYP3A4 modulated DTN-induced toxicity.

![The effect of over-expression and inhibition of CYP3A4 on the cytotoxicity of DCF and DTN in HepG2 and L02 cells. **(A,B)** Over-expression and inhibition of CYP3A4 on the cytotoxicity of DCF and DTN in WT and OE HepG2 cells. **(C,D)** Over-expression and inhibition of CYP3A4 on the cytotoxicity of DCF and DTN in WT and OE L02 cells. Data are represented as mean ± SD (*n* = 3). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. WT groups; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01 OE+KTZ groups vs. OE groups.](fphar-09-01033-g007){#F7}

The Effect of Inhibition and Induction of CYP3A4 on Mouse Liver/Body Weight Ratio, Serum Parameters and Liver Histopathology
----------------------------------------------------------------------------------------------------------------------------

It is well known that metabolic enzymes vary among species. CYP3A11, the isoenzyme of human CYP3A4 in mouse, which occupies the amount of 20% of CYPs, is mainly involved in the metabolism of endogenous and exogenous compounds ([@B7]). The effect of DEX or KTZ on mice CYP3A11 was verified by Q-PCR and Western blot analysis. As shown in **Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}** that the relative mRNA and protein expression level of CYP3A11 in DEX group was significantly increased (about 39%), and vice versa in KTZ group with about 20% decrease in CYP3A11 expression. Meanwhile, DTN treatment had no effect on the CYP3A11 expression. The results showed that the induction or inhibition models were successfully constructed. As shown in **Figure [8A](#F8){ref-type="fig"}**, oral administration of 640 mg/kg DTN with pretreatment of DEX significantly enlarged the liver/body weight ratio compared with the vehicle (at all time-points) and DTN sole group (at 24 h) In addition, In addition, ALT activity was significantly higher at 12 and 24 h in DTN group. And ALT activity in the DTN+DEX group was the greatest at 2 h, followed by a slight decrease from 4 to 12 h, and then was significantly raised at 24 h compared with DTN sole group (**Figure [8C](#F8){ref-type="fig"}**). Meanwhile, the AST activity was higher at 12 and 24 h with significance in DTN+DEX group (**Figure [8E](#F8){ref-type="fig"}**). Nevertheless, pretreatment with KTZ did not significantly decrease the liver/body weight ratio and ALT activity (**Figures [8B,D](#F8){ref-type="fig"}**), except that AST level was significantly decreased after 8 h exposure in DTN+KTZ group compared with DTN group (**Figure [8F](#F8){ref-type="fig"}**).

![The effect of induction and inhibition of CYP3A4 on DTN-induced liver injury in mice. **(A,C,E)** Liver/body weight ratio, ALT and AST activities after exposure to DTN (a single dose of 640 mg/kg) in mice pretreated with DEX. **(B,D,F)** Liver/body weight ratio, ALT and AST activities after exposure to DTN (320 mg/kg for 4 days and 640 mg/kg on the 5th day) in mice pretreated with KTZ. Values are represented as mean ± SD (*n* = 4). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01 vs. DTN group.](fphar-09-01033-g008){#F8}

To supplement serum parameters, histopathological examination was performed for the DTN treatment group as well as vehicle controls. In group A, H&E evaluations suggested that administration of 640 mg/kg DTN caused slight hepatocyte degeneration whereas the livers of control mice appeared normal (**Figure [9A](#F9){ref-type="fig"}**). Mice pretreated with DEX, presented more serious liver injuries with medium hepatocyte degeneration (mainly edema and fatty degeneration) and several even showed slight congestion and inflammatory cell infiltration (labeled with arrows), compared with the mice treated with DEX alone (**Figure [9A](#F9){ref-type="fig"}**). In group B, pretreatment with KTZ before exposure to DTN mitigated liver injury with less degenerated hepatocytes and congestion cells, compared with the mice exposure to vehicle (**Figure [9B](#F9){ref-type="fig"}**). The detailed scores on the liver histopathology in groups A and B were listed in **Supplementary Tables [S5](#SM1){ref-type="supplementary-material"}**, **[S6](#SM1){ref-type="supplementary-material"}**. The histopathological results in combination with biochemical evaluations indicated that KTZ inhibition alleviated injury in mice, whereas, DEX induction aggravated the damage.

![Histopathological evaluation (H&E staining) of liver tissues obtained from mice. Typical images were chosen from each experimental group. **(A)** Livers from mice exposed to DTN (a single dose of 640 mg/kg) in combination with DEX (70 mg/kg) and vehicle. **(B)** Livers from mice exposed to DTN (320 mg/kg for 4 days and 640 mg/kg on the 5th day) in combination with KTZ (75 mg/kg, 1.5 h before the last administration) and vehicle. (Original magnification 100×; the scale bar is 100 μm).](fphar-09-01033-g009){#F9}

Pharmacokinetic of DTN
----------------------

Liquid chromatography-tandem mass spectrometry method was developed and fully validated, which met the requirement of Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation for the determination of DTN in mice biological matrices (**Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}** and **Supplementary Tables [S2](#SM1){ref-type="supplementary-material"}**--**[S4](#SM1){ref-type="supplementary-material"}**). The method was applied to investigate the pharmacokinetic parameters of DTN in mice, including *C*~max~, *T*~max~, AUC, *t*~1/2~, and V*z*/F and CL*z*/*F* with and without KTZ pretreatment, and the parameters were listed in **Table [2](#T2){ref-type="table"}**. Significantly increased AUC (1.54-fold) and higher *C*~max~ (1.58-fold) were observed in mice pretreated with KTZ (**Figure [10](#F10){ref-type="fig"}**).

###### 

Summary of DTN pharmacokinetic parameters obtained in mice with and without pretreatment of KTZ after oral administration of DTN (320 mg/kg for 4 days and 640 mg/kg on the 5th day, *n* = 4).

  Parameter               DTN alone            DTN + KTZ
  ----------------------- -------------------- ----------------------
  *C*~max~ (μg/L)         1162.11 ± 1003.18    1841.40 ± 462.34\*
  *T*~max~ (h)            0.88 ± 0.75          0.70 ± 0.88
  AUC~0-*t*~ (μg/L^∗^h)   7028.68 ± 1992.49    10801.73 ± 3347.78\*
  AUC~0-∞~ (μg/L^∗^h)     14973.15 ± 7375.77   17557.64 ± 5722.71\*
  *t*~1/2~ (h)            19.67 ± 11.63        18.53 ± 10.14
  CL*z*/F (L/h/kg)        0.03 ± 0.02          0.02 ± 0.01
  V*z*/F (L/kg)           0.60 ± 0.15          0.53 ± 0.39
                                               

∗

Significantly different from mice treated with DTN alone (p \< 0.05)

.

![Time-course of measured DTN serum concentrations in mice following oral administration of DTN (320 mg/kg for 4 days and 640 mg/kg on the 5th day) with or without KTZ (75 mg/kg) pretreatment before the last administration. Data are represented as mean ± SD (*n* = 4). ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. DTN group.](fphar-09-01033-g010){#F10}

Discussion
==========

The distribution of furan-containing natural products was extensive in CHMs. Despite of the beneficial effects some furan-containing natural products brought about, cases of hepatotoxicity related to those compounds are daily on the increase and should not be neglected. Actually, the hepatotoxicity of furan-containing compounds, such as teucrin A ([@B10]), 4-ipomeanol ([@B2]), aflatoxin B1 ([@B21]) and toosendanin ([@B49]), had been attributed to the metabolic activation of furan ring. A previous study found that CYP3A4 was the metabolic enzyme mediating bioactivation of the furan ring in toosendanin and yielded a *cis*-butene-1,4-dial intermediate ([@B49]). Considering the molecular structure of DTN possessing a furan ring and was primarily metabolic activated by CYP3A4 ([@B13]), the present study attempted to define the role of CYP3A4 in DTN-induced hepatotoxicity.

*In vitro* cytotoxicity of DTN was evaluated in PHH, HepG2, L02, and NIH3T3 cells. PHH remain differentiated, simultaneously sustain the major drug-metabolizing enzyme activities for a relatively long period of time in culture and afford the most similar excised environment to *in vivo* environment ([@B22]). Simultaneously, the HepG2 and L02 cell lines have been considered a valuable model and are used for risk assessment of toxicants because they retain several liver functions ([@B33]), despite the lower activities of certain drug-metabolizing enzymes in comparison with PHH, such as CYP3A4 and CYP2C9 ([@B44]). However, NIH3T3 cells, derived from mouse embryonic fibroblasts, are lack of CYPs expression ([@B47]; [@B17]). In PHH, the EC~50~ value of DTN was 0.31 mM, which was 1.8 and 2.5 times smaller than that determined in L02 and HepG2 cells, respectively. In addition, DTN was almost non-toxic in NIH3T3 cells with free CYP3A4 expression presented as the irregular cytotoxicity ranging from 74.4 to 94.7% at different concentrations. Moreover, the cell viability was slightly decreased until up to 72 h incubation to evaluate the EC~50~ values. Toxicities expressed with EC~50~ values in PHH, L02, HepG2, and NIH3T3 cells were consistent with CYP3A4 expression levels in those cells, indicating that cytotoxicity required the participation of CYP3A4.

Furthermore, PHH were co-treated with the common *in vitro* specific inhibitor (KTZ) ([@B50]) and inducer (RIF) of CYP3A4 ([@B51]) to investigate the effect of CYP3A4 on DTN-induced cytotoxicity. It has been reported that a known hepatotoxic drug, DCF, caused hepatotoxicity through metabolic activation by CYP3A4. Therefore, DCF was chosen to serve as the positive control in this experiment. Theoretically, inhibition of CYP3A4 could mitigate cytotoxicity and induction aggravated cytotoxicity. The cell viability in the DCF+KTZ group was increased compared to the DTN group, presented as the increased EC~50~ value; while opposite results were observed in the RIF group, which was consistent with our speculation. With regard to DTN, all tested concentrations (100--800 μM) significantly increased cell viability after pretreatment with KTZ, and induction with DEX notably decreased the cell viability. It could be assumed that CYP3A4 plays a important role in the toxicity of DTN.

To verify the relationship between CYP3A4 and toxicity in depth, CYP3A4 OE HepG2 and L02 cells were established and certificated by measuring the expression of CYP3A4 on the mRNA and protein levels, as well as determination of the CYP3A4 activity. Results showed that the mRNA level was significantly higher in both the OE cells, and the metabolic activity in OE HepG2 and L02 cells was 3--11 times and 13--41 times significantly higher than in the respective WT cells (**Figure [6](#F6){ref-type="fig"}**). Comparison of cytotoxicity in OE and WT cells was performed based on the successfully established cells. The cytotoxicity in OE HepG2 and L02 cells was concentration-dependent, and the cell viabilities in OE cells treated with DCF and DTN both showed a significant decrease at tested concentrations compared with the corresponding WT cells. Additionally, the decrease in both the OE cells could be reversed by inhibition of CYP3A4 with KTZ. In combination with the results in PHH, it is evident that the up- and down-regulation of CYP3A4 were involved in the development of toxicity induced by DTN metabolic activation, namely high expression of CYP3A4 aggravated the cytotoxicity, and vice versa. To address the role of enzyme in detail, *in vivo* experiments in mice were further performed.

The recommended dosage of DC is 83--167 mg/kg/day for a 60 kg adult according to the Chinese Pharmacopoeia ([@B8]). However, the clinical application of DC in prescription has been recently questioned, and it has been suggested that the therapeutic dose should be 250--833 mg/kg/day ([@B14]; [@B41]). Accordingly, the equivalent dose for DTN in mice is approximately 0.9--3.0 mg/kg daily based on the content of DTN (0.03%) in DC ([@B48]). On account of the fact that DC related liver injury was a result of a long term and over-dose use, herein, in order to make acute toxicity models for single dose in this study, DTN was orally administrated at doses of approximately 80 times (320 mg/kg) and 160 times (640 mg/kg) higher than the highest dose used in clinic. Because CYP3As in the gut wall also have the potential to metabolize DTN, which may limit the understanding of the important role of hepatic CYP3As in the metabolism of DTN, it is justifiable to make the bioavailability and distribution of DTN after oral administration clear. As demonstrated ([@B42]), the absolute bioavailability of DTN from oral administration was determined as 47.9%, suggesting a very high proportion of DTN was absorbed into body's circulation. Furthermore, the results on distribution showed that DTN was mostly distributed in the liver (twofold higher than in small intestine) after a rapid absorption. Although it is possible that the gut microbiota and intestinal P450 enzymes partially contribute to the metabolism of DTN, the above evidence suggested that DTN was mainly metabolized in liver. It is well known that ALT and AST activity are reliable and sensitive indicators of hepatocellular type of liver injury, as well as alkaline phosphatase (ALP) activity is a biomarker for cholestasis and bile duct injury ([@B31]). Administration of DTN until at a dose of 640 mg/kg elevated ALT and AST levels in mice, but did not change ALP levels (**Supplementary Figures [S4](#SM1){ref-type="supplementary-material"}**, **[S5](#SM1){ref-type="supplementary-material"}**). The alterations in biochemical parameters were in accordance with symptoms in cases of DC-induced liver injury, which were clinically diagnosed as hepatocellular type instead of cholestatic type of HILI ([@B23]).

Moreover, we further established induction model or a repeated administration model for inhibition experiments in mice. The relative mRNA expression and hepatic CYP3A11 expression were up-regulated by potent inducer DEX (**Supplementary Figure [S2B](#SM1){ref-type="supplementary-material"}**). Mice pretreatment with DEX for 3 consecutive days as induction model were established. Changes in liver/body weight ratio were used as a direct indicator of liver injury, and pretreatment with DEX significantly increased liver/body weight ratio at 24 h. Furthermore, ALT level was significantly elevated within 24 h, except a slight decrease at 8 h exposure of DTN. Meanwhile, AST level was significantly elevated up to 24 h in DEX group. In addition, more severe histopathological injury with medium hepatocyte degeneration, slight congestion and inflammatory cell infiltration was observed in the DEX group, which indicated that induction of CYP3A4 aggravated liver injury.

On the contrary in the inhibition experiment, mice orally administrated with DTN at a dose of 320 mg/kg for 4 days and 640 mg/kg on the 5th day resulted in hepatocellular degeneration and congestion. However, no change of CYP3A11 expression was observed in mice treated with DTN (**Supplementary Figure [S2C](#SM1){ref-type="supplementary-material"}**), which might be due to the short time of administration. Moreover, a down-regulation of CYP3A11 expression (**Supplementary Figure [S2C](#SM1){ref-type="supplementary-material"}**) and mild toxic symptoms were observed in mice pretreated with KTZ on the 5th day, including a decrease in serum AST level and alleviation of hepatic degeneration compared with other regimen. Interestingly, the inconspicuous decrease of ALT and AST levels in KTZ group may be contributed to the fact that the biochemical factors are more sensitive, inhibition by KTZ presented a decrease of ALT and AST after 4 h exposure to DTN, and it lasted to 8 h. Afterwards, not only the debilitating down-regulating effect of KTZ but also the self-regulation of body brought about the dynamic recovery of ALT and AST level. Nevertheless, the liver histopathological response was slower and more reflective of the injury that inhibition by KTZ could mitigate hepatocellular degeneration and congestion to some extent. Therefore, the *in vivo* results in depth illustrated that CYP3A4 participated in and modulated DTN-induced toxicity.

Due to the fact that DTN could be metabolized via CYP3A4 (phase I metabolism), the change in CYP3A4 expression might not only influence the phase I metabolism of DTN, but also alter serum concentration of DTN as well. Therefore, the serum concentration of DTN was measured by LC-MS/MS. Pharmacokinetic data showed larger AUCs and higher *C*~max~ of DTN in serum of DTN+KTZ group compared with DTN group alone, which suggested that the inhibition of CYP3A4 led to the enhancement of absorption of DTN *in vivo*. However, higher *C*~max~ and larger AUCs of DTN were not accompanied by more potent hepatotoxicity (**Figures [8F](#F8){ref-type="fig"}**, **[9B](#F9){ref-type="fig"}**), that is to say mice pretreated with KTZ were less susceptible to DTN-induced hepatotoxicity, which further implicated that CYP3A4 participated in the process of DTN-induced hepatotoxicity and metabolic intermediate rather than the parent drug was likely to exert the toxicity. There is a serious concern that multiple clinically relevant drug interactions with CHMs can occur in HILI cases ([@B37], [@B38]). Herb--drug interactions may change the available affinity of specific receptor or systemic pharmacokinetic actions of drug, including absorption, distribution, metabolism and excretion. Therefore, the present study offers valuable reference when DC is clinically prescribed for combination therapy.

Conclusion
==========

In summary, exposure to DTN exhibited liver injury in both cells and mice. Induction of CYP3A4 aggravated toxic effects *in vitro* and *in vivo*, whereas inhibition of CYP3A4 attenuated the hepatotoxicity. This work provides insights into the role of CYP3A4 in the DTN-induced liver injury, which would be helpful to comprehensively illustrate the relationship between the toxic actions of DTN and metabolic activation. However, the relative weak, albeit statistically significant effects of induction/inhibition and over-expression of CYP3A4 on DTN cytotoxicity suggest that non-CYP3A4 drug metabolizing enzyme may also play a role in DTN-induced toxicity. Further study on detecting the metabolic activated intermediates, thoroughly characterizing the DTN metabolic activated adducts *in vivo* and *in vitro* and ascertain the relationship between adduct and hepatotoxicity should be performed.
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